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To the Editor:
The evidence-based clinical prac-
tice guideline on molecular testing for 
the selection of lung cancer patients 
for epidermal growth factor recep-
tor (EGFR) and anaplastic lymphoma 
kinase tyrosine kinase inhibitors by the 
College of American Pathologists, the 
International Association for the Study 
of Lung Cancer, and the Association 
for Molecular Pathology recommends 
that patients with lung adenocarcinoma 
should not be excluded from testing 
based on clinical characteristics that 
include ethnicity, smoking history, and 
sex.1 We totally agree with this rec-
ommendation as our experience and 
findings also show that sex and smok-
ing history are not sensitive or specific 
enough to exclude individual patients 
from testing even though in our patients, 
EGFR mutations were more frequent in 
women (52.5%) than in men (27.8%) 
and more frequent in never smokers 
(54.8%) than in ever smokers (20.7%).2
EGFR mutations are rare in well-
characterized, fully excised surgical 
specimens of squamous cell lung car-
cinoma lacking any adenocarcinoma 
component with a reported frequency 
of less than 5%.1 In the case of limited 
lung cancer specimens by small biopsies 
where the possibility of an adenocarci-
noma component cannot be completely 
excluded, the guideline recommends 
that EGFR mutation testing may be per-
formed in cases showing squamous cell 
histology with clinical characteristics 
such as young age and a lack of smok-
ing history.1 From our experience with 
small biopsy specimens taken during 
flexible bronchoscopy or transcuta-
neous needle biopsy in patients with 
advanced-stage non–small-lung can-
cer, EGFR mutations were detected 
with the use of real-time polymerase 
chain reaction based on Scorpion® and 
Amplification Refractory Mutation 
System® technologies in 39.4% of ade-
nocarcinoma from 132 patients whereas 
only one (9.1%) of 11 squamous cell 
carcinomas was EGFR-mutation posi-
tive. The only EGFR-mutation–positive 
squamous cell carcinoma was from a 
never smoker whereas the squamous 
cell carcinomas from all 10 smokers 
were EGFR-mutation negative.3
Other expert panels4 recommend 
that apart from nonsquamous NSCLC, 
EGFR mutation testing should be per-
formed in squamous cell carcinoma 
patients with clinical features associ-
ated with higher prevalence of EGFR 
mutations such as a lack of smoking 
history. Furthermore, adenosquamous 
carcinomas and solid adenocarcinomas, 
in which EGFR mutations have been 
reported, can mimic squamous cell car-
cinoma in small biopsy specimens.5 
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To the Editor:
We read with great interest the 
article published by Errihani et al. on 
the spectrum of epidermal growth factor 
receptor (EGFR) mutation in Moroccan 
patients (n = 137) with lung adenocar-
cinoma (AC), and we would like to con-
gratulate them for their very important 
study which in our knowledge represent 
the first study in Morocco and Arab 
population.
In Morocco, lung cancer represents 
the first cause of cancer in men1,2 and the 
ninth cause of cancer in women.2 AC is 
the second most common histological 
subtype after squamous-cell carcinoma 
according to the Casablanca registry, rep-
resenting 26% of all lung cancers (24.7% 
in men and 36.9% in women [most com-
mon histology in women]).2
The authors showed that the 
overall frequency of the EGFR muta-
tion was 21%, which is higher than 
that in white population (11%–
13.7%).3–6 Mutations were mainly 
detected in the exon 19 (69%), fol-
lowed by exon 21 (21%) and exon 
20 (7%), whereas mutations in the 
LETTERS TO THE EDITOR
